Adverse Events Following Immunization (AEFI) Quarterly Report for 2015 – Q2
Safety assessment summary for Quarter 2:
- No vaccine safety signals were identified in Quarter 2 of 2015.
- All AEFI reports describing a serious event were reviewed and most found either to be expected (based on known vaccine-related adverse reactions) or to have alternate explanations not related to vaccination.
- As in recent quarterly reports, the total count of AEFI reports received remains lower than seen in historic data, reflecting a gap in reporting from some jurisdictions that are implementing electronic reporting systems.
Vaccines are closely monitored in Canada at all phases of the vaccine product ‘life cycle’ from discovery through market authorization (pre-market) and beyond, as people begin using them (post-market). Many stakeholders are involved in various activities related to vaccine safety assessment and monitoring including the federal government, provincial, territorial and local public health authorities, health care providers, vaccine industry and the public. The Public Health Agency of Canada (the Agency) conducts vigilant post-market safety surveillance through a national reporting system, the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS).
An Adverse Event Following Immunization (AEFI) is defined as any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine. The adverse event may be any unfavorable or unintended sign, abnormal laboratory finding, symptom or disease. Serious AEFI are those which are life-threatening, result in hospitalization or a prolongation of hospitalization, result in persistent or significant disability, or where the outcome is a birth defect or death.
The primary purpose of vaccine post market surveillance is to detect safety concerns. These concerns include a possible increase in the severity or frequency of expected AEFIs, or occurrence of one or more unexpected events (i.e. an event that is not consistent with Canadian product information or labelling). This allows immunization providers and public health immunization program providers to take public health action at the level of the:
- individual (e.g. further investigation to confirm a diagnosis and determine possible causes, consultation to rule out allergy to one or more vaccine components, or evaluate whether or not to give subsequent doses of a vaccine), and/or
- immunization program (e.g. investigation of a cluster of adverse events, review of procedures to ensure that vaccine storage requirements have been strictly followed, or consider a change in policy to adopt a less reactogenic vaccine).
The Agency also shares AEFI data with Health Canada, the vaccine regulator in Canada, to enable regulatory action related to vaccines marketed in Canada. These actions may include issuing communications to immunization providers or the public regarding the safety concern or requiring additional information or investigation by the vaccine distributor.
Vaccine safety surveillance reports summarizing CAEFISS data are released by the Agency on a routine basis. The Quarterly Reports summarize all AEFI reports received by the Agency from January 1st to March 31st (Quarter 1), April 1st to June 30th (Quarter 2), July 1st to September 30th(Quarter 3) and October 1st to December 31st (Quarter 4), regardless of the date the vaccine was given. In addition, the Quarter 4 Report provides cumulative data spanning the entire year and contains a more detailed review of any concerns that may have been observed in the earlier reports.
In order to provide a general idea of how the data may vary from year to year, each Quarter’s data are shown along with an average of the preceding prior years’ Quarterly data (in other words, the data in this quarter, Quarter 2, are shown along with the average Quarter 2 data from previous years). However, because these data reflect reports received in the particular quarter, and not necessarily when the vaccine was given, they can be subject to wide variations depending on when and how reports are received, processed and forwarded by provincial/territorial public health authorities. Therefore the ability to compare and interpret patterns in these data are limited and the purpose of this report is to provide only a data snapshot.
Notes on interpretation: AEFI reports submitted to the Public Health Agency of Canada represent a suspicion, opinion or observation by the reporter as opposed to an assertion or proof that the vaccine may have caused the event. For most events, a clear causal relationship is difficult to establish. Additional limitations to AEFI report data include varied reporting standards and underreporting, lack of certainty regarding the diagnostic validity of a reported event, missing information regarding other potential causes, and other reporting biases.
Results Highlighted for Quarter 2 of 2015
Counts included in this Quarterly Report (Q2) include reports received from April 1st to Jun 30th, 2015 and comparisons are made to the average number of reports received in the same quarter over the previous four years (2011-2014). The reports analysed were extracted from the CAEFISS database on June 30th, 2015 by the Public Health Agency of Canada (the Agency).
Number of AEFI and Serious AEFI Reports
Frequency of Serious and Non-serious AEFI Reports by Age Group
Again in Quarter 2, there were changes in the age distribution for serious AEFI reports received relative to previous years. As shown in Table 1, the proportion of all serious AEFI reports for children one to less than two years of age was higher in Quarter 2 of 2015 than the previous four year average (19 versus 13). This change may be due in part to the recent implementation of new hexavalent vaccines (DTaP-IPV-HB-Hib), which typically have increased AEFI reporting rates. (See Table 3 below).
|Age Group||Serious Adverse Events (SAE)||Non-serious Adverse Events (non-SAE)|
|2015||Mean for 2011-2014||2015||Mean for 2011-2014|
Type of AEFI Reported by Level of Seriousness
The main type of AEFI reported by level of seriousness for Quarter 2 of 2015 compared to the 2011-2014 average is shown in Table 2. As in previous years, neurologic events (most often seizure) followed by systemic events (i.e., events involving many body systems often accompanied by fever), were the most frequently reported serious AEFIs in Quarter 2 of 2015.
|Main AEFI reported||Number of Serious Adverse Event Reports||Number of Non-serious Adverse Event Reports|
|2015||Average for 2011-14||2015||Average for 2011-14|
|Reaction at or near the vaccination site||2||7||207||255|
|Allergic or allergic-like events||0||2||44||78|
|Other events specified on the CAEFISS form||5||6||19||33|
|Vaccination anxiety related events||0||0||6||7|
|Miscellaneous other events||11||5||25||56|
|Vaccination error without an associated AEFI||0||0||0||13|
Most common vaccines administered in AEFI Reports
Table 3 lists the most commonly administered vaccines among AEFI reports received for Quarter 2 of 2015 relative to the average for Quarter 2 of 2011-2014. The most notable change, as pointed out above, was a higher number of serious AEFI reports following several vaccines including DTaP-HB-IPV-Hib, PneuC and Rota, and of non-serious AEFI following zoster, all having increased distribution. As newly introduced vaccines, their use is greater in recent quarters relative to the average that includes older quarters.
|Vaccines administered||Number of Serious Adverse Event (SAE) Reports Received||Number of Non-Serious Adverse Event (non-SAE) Reports Received|
|2015||Average for 2011-14||2015||Average for 2011-14|
Table 3 Footnotes
Totals add up to more than the total number of reports as one report may involve more than one vaccine.
DTaP-HB-IPV-Hib - Combined Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (recombinant), Inactivated Poliomyelitis and adsorbed conjugated Haemophilus influenzae type b.
DTaP-Hib - Diphtheria and Tetanus Toxoids, acellular Pertussis, Haemophilus influenzae type b.
DTaP-IPV - Component Pertussis vaccine and Diphtheria and Tetanus Toxoids adsorbed, combined with Inactivated Poliomyelitis vaccine.
DTaP-IPV-Hib - Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Combined with Inactivated Poliomyelitis Vaccine and Haemophilus b Conjugate Vaccine.
|Cholera-Ecoli oral (Chol-Ecol-O)||0||<1||2||3|
|HA (Hepatitis A)||0||<1||9||15|
|HA-Typh (HA Typhoid)||0||0||2||2|
|HAHB (Hepatitis A Hepatitis B)||0||1||21||27|
|HB (Hepatitis B)||1||2||35||48|
|HPV (Human Papilloma Virus)||0||2||28||48|
|Hib (Hemophilus influenza type b)||0||<1||5||2|
|MenC (Men Conjugate)||14||15||60||130|
|MenP (Men Polysaccharide)||0||<1||1||0|
|PneuC (Pneu Conjugate)||25||19||56||156|
|Td (Tetanus diphtheria||0||<1||9||16|
|Td-IPV (Adult Tetanus Inactivated Polio)||0||0||1||3|
|Tdap (Adult Tetanus diphtheria acellular Pertussis)||1||2||44||72|
|Tdap-IPVTable 3 Footnote *||1||0||11||18|
|YF (Yellow Fever)||0||<1||4||5|
This Quarter 2 report of four planned for 2015 is based on reports of adverse events received at the Agency from provincial/territorial public health authorities and active, pediatric hospital based surveillance. Detailed evaluation of the reports and reporting patterns in collaboration with provincial/territorial vaccine safety focal points on the VVWG and Health Canada have not identified any vaccine safety signals of concern. The tables and figures in this report provide a snapshot of the data reviewed and provide an overview of vaccine safety reporting in Canada.
- Date modified: